Personalized Androgen Deprivation Therapy – 

Dr. Keane presents clinical considerations in the treatment of men with advanced prostate cancer when selecting an androgen deprivation treatment from therapy. 

Announcing an actively recruiting clinical trial:
A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist). 

The PRONOUNCE trial will compare the occurrence of major adverse cardiovascular events (MACEs) in patients with prostate cancer and cardiovascular disease (CVD), receiving the GnRH receptor antagonist, degarelix, to patients receiving a GnRH receptor agonist, leuprolide. The collaborators for this study are Memorial Sloan Kettering Cancer Center with Principal Investigator, Howard Scher, MD. and Duke Clinical Research Institute with Principal Investigator  Matthew Roe, MD, MHS. 

For More Information on this trial, including clinical trial site locations that are current click below:
 

Pooled Data from Trials Comparing Degarelix with LHRH Agonist in Men with Advanced Prostate Cancer

Laurence Klotz, MD. Professor of Surgery, University of Toronto
Urologic Oncologist, Sunnybrook Health Sciences Centre presents this analysis comparing the LNRH agonists with the GnRH antagonists, specially degarelix.